MediCardia Health has integrated wearable ECG from US Food and Drug Administration (FDA)-approved consumer devices for remote monitoring of individuals with, or at risk of, atrial fibrillation (AF).
This is claimed to streamline AF care through remote monitoring and virtual health services.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Atrial fibrillation is a heart rhythm disorder that impacts over 40 million individuals globally.
This condition escalates the likelihood of stroke by five times, and such strokes frequently result in fatality or profound impairment.
Froedtert Pleasant Prairie Hospital cardiac electrophysiology medical director Indrajit Choudhuri said: “Clinical trials have demonstrated the benefit of both implanted devices as well as consumer wearables and handheld devices in screening for AF.
“Early detection of atrial fibrillation leveraging consumer devices that millions of people already have or have easy access to, could identify and prevent stroke in millions at risk, and is more acceptable to patients than repeated visits to a physician’s office, emergency room or hospital to obtain an ECG.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe new feature is said to be part of MediCardia’s cardiovascular disease management approach, using remote monitoring, virtual care, clinical intelligence, and analytics to align healthcare organisations’ population health objectives with personalised patient strategies.
In addition, MediCardia Health is partnering with Caerus Strength to develop a sensor-embedded strength vest for combating Sarcopenia.
Caerus Strength has designed a chest-worn vest with embedded sensors that helps strengthen individuals dealing with sarcopenia, cardiovascular health issues, and recovery from heart-related events.
